Amylin Pharmaceuticals, Inc. (AMLN) Says New Diabetes Injection Meets Main Goal (BioSpace, 31 October 2007)

14 Nov 2007

Amylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. have said that they have found positive results from a 30-week comparator study of once-weekly exenatide long-acting release injection and BYETTA(R) (exenatide) injection taken twice daily in patients with type 2 diabetes.